Trial reportThe Journal of urology2026
Impact of Renal Mass Biopsy on Decision-Making Experience for Clinical T1 Renal Masses.
Trial report in The Journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
purposeOwing to uncertainty on best management, a subset of patients with small renal masses suspicious for kidney cancer experience elevated decisional conflict. We hypothesize that pathologic information from renal mass biopsy (RMB) may improve patient decision-making. In this study, we evaluate the impact of RMB on decisional conflict for patients with clinical T1 renal masses. MATERIALS AND
methodsA comparative, nonrandomized clinical trial was performed at a large tertiary cancer center. Patients with new clinical T1 renal masses were self-assigned to standard-of-care biopsy. We used difference-in-difference (DiD) analyses to assess change in decisional conflict scale by receipt of RMB.
resultsAmong 250 participants, 25% underwent biopsy during the initial decision-making period before definitive intervention. Biopsy was more common for patients with masses > 4 cm vs 0 to 2 cm (prevalence ratios [PR] 2.41, 95% CI: 1.20-4.82,
conclusionsThough RMB did not significantly decrease decisional conflict in all patients, biopsy reduced decisional conflict in certain patient subsets, demonstrating the importance of further investigating how to better support patients after renal mass diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.